Soligenix Files S-1 with SEC

TL;DR

Soligenix (SNGX) filed its S-1, giving investors the latest on their pharma biz.

AI Summary

Soligenix, Inc. filed an S-1 form on July 24, 2024, detailing its business and financial status. The company, formerly known as Dor Biopharma Inc. and Immunotherapeutics Inc., is in the pharmaceutical preparations industry. Its principal executive offices are located in Princeton, NJ. The filing includes financial data and information related to its common stock and preferred stock.

Why It Matters

This S-1 filing provides a comprehensive overview of Soligenix, Inc.'s business operations, financial health, and strategic direction, which is crucial for investors and stakeholders to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company filing an S-1, Soligenix is likely in a growth or development phase, which inherently carries higher risks related to clinical trials, regulatory approvals, and market adoption.

Key Numbers

• 0000812796 — Central Index Key (Unique identifier for Soligenix, Inc. with the SEC.)
• 2834 — Standard Industrial Classification (Industry code for Pharmaceutical Preparations.)

Key Players & Entities

• SOLIGENIX, INC. (company) — Filer
• DOR BIOPHARMA INC (company) — Former Company Name
• IMMUNOTHERAPEUTICS INC (company) — Former Company Name
• 29 EMMONS DRIVE, SUITE B-10, PRINCETON, NJ 08540 (company) — Business and Mail Address
• 609-538-8200 (company) — Business Phone Number
• 20240724 (date) — Filing Date
• 2023-05-09 (date) — Public Offering Date

FAQ

Key Financial Figures

• $0.001 — 54,688 shares of common stock par value $0.001 per share ("Common Stock") of Soligenix
• $6.00 — ur Common Stock at an exercise price of $6.00 per share for a period of five years fr
• $6.07 — Stock on the Nasdaq Capital Market was $6.07 per share. Investing in our securities
• $1.00 — maintain a minimum closing bid price of $1.00 for 30 consecutive trading days. On D
• $13,840,256 — securities and publicly held shares was $13,840,256 and $13,836,201, respectively. As of Ma
• $13,836,201 — ublicly held shares was $13,840,256 and $13,836,201, respectively. As of March 31, 2024, we
• $7,091,548 — 24, we had cash and cash equivalents of $7,091,548, working capital of $607,499 and total
• $607,499 — lents of $7,091,548, working capital of $607,499 and total liabilities of $7,290,013, of
• $7,290,013 — al of $607,499 and total liabilities of $7,290,013, of which over 41.1% was owed under our
• $250 million — on Stock held by non-affiliates exceeds $250 million as of the prior June 30, or (2) our ann
• $100 million — 30, or (2) our annual revenues exceeded $100 million during such completed fiscal year and t
• $700 million — on Stock held by non-affiliates exceeds $700 million as of the prior June 30. 5 Table of C
• $6.40 — arrants) at a weighted average price of $6.40 per share, of which warrants to purchas
• $84.65 — at a weighted average exercise price of $84.65 per share, of which options to purchase
• $2,059,309 — shares issuable upon the conversion of $2,059,309 of principal and $9,080 of accrued inte

Filing Documents

• sngx-20240331xs1.htm (S-1) — 3463KB
• sngx-20240331xex5d1.htm (EX-5.1) — 22KB
• sngx-20240331xex21d1.htm (EX-21.1) — 10KB
• sngx-20240331xex23d1.htm (EX-23.1) — 4KB
• sngx-20240331xex23d2.htm (EX-23.2) — 3KB
• sngx-20240331xexfees.htm (EX-FILING FEES) — 27KB
• sngx-20240331xs1001.jpg (GRAPHIC) — 7KB
• sngx-20240331xs1004.jpg (GRAPHIC) — 1KB
• sngx-20240331xs1005.jpg (GRAPHIC) — 1KB
• sngx-20240331xs1020.jpg (GRAPHIC) — 4KB
• 0001558370-24-010061.txt ( ) — 15038KB
• sngx-20240331.xsd (EX-101.SCH) — 80KB
• sngx-20240331_cal.xml (EX-101.CAL) — 65KB
• sngx-20240331_def.xml (EX-101.DEF) — 515KB
• sngx-20240331_lab.xml (EX-101.LAB) — 570KB
• sngx-20240331_pre.xml (EX-101.PRE) — 772KB
• sngx-20240331xs1_htm.xml (XML) — 2105KB

RISK FACTORS

RISK FACTORS 10 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA AND MARKET INFORMATION 34

USE OF PROCEEDS

USE OF PROCEEDS 36 DIVIDEND POLICY 36 MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS 36

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 38

BUSINESS

BUSINESS 49 MANAGEMENT 81

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 87 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 92

SECURITY OWNERSHIP OF MANAGEMENT AND OTHER BENEFICIAL OWNERS

SECURITY OWNERSHIP OF MANAGEMENT AND OTHER BENEFICIAL OWNERS 93 SELLING STOCKHOLDERS 94 PLAN OF DISTRIBUTION 97

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 98 LEGAL MATTERS 102 EXPERTS 102 WHERE YOU CAN FIND MORE INFORMATION 103 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a resale registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the "SEC"). This prospectus includes important information about us, the securities being offered and other information you should know before investing in our securities. You should also read and consider information in the documents we have referred you to in the sections of this prospectus entitled "Where You Can Find More Information." You should rely only on the information contained in this prospectus (as supplemented and amended). We have not authorized anyone to provide you with different information. We take no responsibility for, and can provide no assurances as to the reliability of, any other information that others may give you. The information contained in this prospectus (and in any supplement or amendment to this prospectus) are accurate only as of their respective dates, regardless of the time of delivery of this prospectus, any applicable prospectus supplement, or any sale of a security. We urge you to read carefully this prospectus (as supplemented and amended), before deciding whether to invest in any of the Common Stock being offered. This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the section entitled "Where You Can Find More Information." We further note that the representations, warrantie

View Full Filing

View this S-1 filing on SEC EDGAR